Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection

Hepatology Research

Volumn 33, Issue 2, 2005, Pages 167-170

  Buckingham, Robin E ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adiponectin; Hepatic steatosis; NASH; Stellate cells; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; MATRIX PROTEIN; TROGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; FATTY LIVER; GLUCOSE METABOLISM; HEPATITIS; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; IN VITRO STUDY; INSULIN SENSITIVITY; LIVER FIBROSIS; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; STELLATE CELL; TISSUE REGENERATION;

EID: 29144461456     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2005.09.027     Document Type: Article

References (24)

1. P. Zimmet K.G.M.M. Alberti J. Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782-787
2. National Task Force on the Prevention Treatment of Obesity. Overweight, obesity, and health risk Arch Intern Med 160 2000 898-904
3. G. Marchesini E. Bugianesi G. Forlani et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome Hepatology 37 2003 917-923
4. K.G. Tolman V. Fonseca M.H. Tan A. Dalpiaz Narrative review: hepatobiliary disease in type 2 diabetes mellitus Ann Intern Med 141 2004 946-956
5. G. Alberti P. Zimmet J. Shaw et al. Type 2 diabetes in the young: The evolving epidemic Diabetes Care 27 2004 1798-1811
6. N. Kerkar Non-alcoholic steatohepatitis in children Pediatr Transplant 8 2004 613-618
7. H.E. Lebovitz M. Kreider M.I. Freed Evaluation of liver function in type 2 diabetic patients during clinical trials Diabetes Care 25 2002 815-821
8. J.M. Lehmann L.B. Moore T.A. Smith-Oliver W.O. Wilkison T.M. Willson S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ) J Biol Chem 270 1995 12953-12956
9. S.A. Kliewer K. Umesono D.J. Noonan R.A. Heyman R.M. Evans Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors Nature 358 1992 771-774
10. G. Chinetti J.C. Fruchart B. Staels Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation Inflamm Res 49 2000 497-505
11. M. Tiikkainen A.-M. Hakkinen E. Korsheninnikova T. Nyman S. Makimattila H. Yki-Jarvinen Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes Diabetes 53 2004 2169-2176
12. M. Bajaj S. Suraamornkul P. Piper et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients J Clin Endocrinol Metab 89 2004 200-206
13. J.M. Hui A. Hodge G.C. Farrell J.G. Kench A. Kriketos J. George Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 40 2004 46-54
14. B.A. Neuschwander-Tetri E.M. Brunt K.R. Wehmeier D. Oliver B.R. Bacon Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone Hepatology 38 2003 1008-1017
15. K. Promrat G. Lutchman G.I. Uwaifo et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188-196
16. A. Galli D.W. Crabb E. Ceni et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro Gastroenterology 122 2002 1924-1940
17. A. Masamune K. Kikuta M. Satoh Y. Sakai A. Satoh T. Shimosegawa Ligands of peroxisome proliferator-activated receptor-γ block activation of pancreatic stellate cells J Biol Chem 277 2002 141-147
18. B. Guo D. Koya M. Isono T. Sugimoto A. Kashiwagi M. Haneda Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells Diabetes 53 2004 200-208
19. N. Sattar O. Scherbakova I. Ford et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study Diabetes 53 2004 2855-2860
20. D.H. Lee K. Silventoinen D.R. Jacobs P. Jousilahti J. Tuomileto γ-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women J Clin Endocrinol Metab 89 2004 5410-5414
21. M.-C. Alessi D. Bastelica A. Mavri et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation Arterioscler Thromb Vasc Biol 23 2003 1262-1268
22. A. Festa R. D'Agostino R.P. Tracy S.M. Haffner Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. The insulin resistance atherosclerosis study Diabetes 51 2002 1131-1137
23. A.M. Thogersen J.-H. Jansson K. Boman et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor Circulation 98 1998 2241-2247
24. H. Yki-Jarvinen A. Sutinen A. Silveira et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy Arterioscler Thromb Vasc Biol 23 2003 688-694